What is PS R3 Peptide? Mechanism, Structure & Research Overview

Written by Marion Kessler · Reviewed by Douglas ReyesIndependent compilation of public literature; no institutional affiliation.

Corrections welcome. If a summary here misreads a paper, a note with the citation gets it fixed in the next pass. The notebook answers questions about its own sources only - never about sourcing, dosing or anything clinical.

I started this notebook because one question kept coming back without an answer attached to it. Every time I wrote down what is ps r3 peptide, I produced a slightly different answer, and not one of those answers came from a source I could open and check. That is an uncomfortable position to be in when the material in question is a synthetic peptide sold into laboratories. So I did the slow thing and went back through vendor documentation, methods sections, analytical chemistry papers and receptor pharmacology reviews, separating what was measured from what was merely asserted.

What I found is that the code itself is the problem. PS R3, PS T2 and PS CG appear together on supplier lists as if they were a family, but the public record does not fix a single accepted sequence, identifier or structure for any of them. There is no registry entry I can point to, no deposited coordinates, no consensus formula. That absence is not a gap I can fill by guessing, and I am not going to fill it by copying a number off a catalogue page and presenting it as established fact.

This page is therefore a reading record rather than a product page. I say which claims come from lot documentation I actually held, which come from peer-reviewed work on related compounds, and which are my own inference. Everything below concerns laboratory research material only. If you came here asking what is ps r3 peptide, the honest short answer is that the name is better documented than the molecule, and the rest of these notes explain why I think that distinction matters.

What is ps-r3 peptide, and where the code sits in the PS naming scheme

The PS prefix is the only piece of these codes I feel reasonably comfortable with, and even that is inference from how the three names sit together on supplier lists rather than anything a registry told me. PS R3, PS T2 and PS CG are grouped as if they belong to one vendor series, with a letter plus number suffix separating the members. My reading is that the letter marks a family and the number marks an iteration: r3 would be the third entry in one line, t2 the second entry in a parallel line, and cg something that sits outside both. I want to be plain about the status of that reading. It is a pattern I noticed in catalogue layout, not a published convention, and no document I have seen states it.

When someone asks what is ps r3 peptide, the naming ambiguity is usually the first thing they are actually bumping into, because the code carries no chemical information at all. A real peptide designation normally tells you something: an INN tells you the class, a sequence tells you the composition, a CAS number tells you the registry entry. ps r3 tells you none of these. The most useful thing I did early on was to stop treating the code as a description and start treating it as a label attached to lots of material whose composition has to be established independently, batch by batch.

I keep two sibling notes for the other members of the series, ps t2 peptide and ps cg peptide, because comparing the three is the only way I have found to say anything defensible about any one of them. Where the vendor text for one member overlaps with another, the overlap is usually marketing copy rather than chemistry, and I discount it accordingly. Everything here concerns laboratory handling and literature reading only; none of it is a protocol for human or animal administration.

How I read the three PS codes, and how much of that reading is verifiable
Code	How I read the suffix	What I can verify publicly	What stays my own inference
PS R3	r marks a family, 3 an iteration within it	The name appears in supplier catalogues; no registry entry fixes a sequence or identifier	That the number encodes an actual iteration order
PS T2	t marks a second, parallel family	Appears alongside PS R3 in the same series listings	That the t and r families share a scaffold
PS CG	cg reads as a modified or conjugated variant	Appears in the same series; even less descriptive material exists	That cg is anything other than another label

Amino acid sequence and molecular formula: what the record actually fixes

Here is the part most pages skip, and the part I think matters most. I have not found an authoritative published sequence for ps r3. I have not found a deposited structure, a registry entry with a defined composition, or a peer-reviewed paper that states a residue list. When I write that the public record does not fix a single accepted value for this, I mean it literally: different lots, different vendors and different catalogue snapshots disagree, and there is no referee I can identify between them. The batch certificates I have read usually report a molecular ion, but the values are not consistent across lots, and I treat none of them as an authoritative fixed value for the compound.

That does not make the material unstudied. It makes the identity question an analytical one rather than a bibliographic one. If I wanted to establish what is in a given vial, the routes are standard and I can name them: tandem mass spectrometry with de novo or database-assisted interpretation of fragment ladders, amino acid analysis after acid hydrolysis for composition, Edman degradation for N-terminal order, and high-resolution mass measurement for the intact mass. Each has failure modes. Hydrolysis destroys trp and converts asn to asp; Edman stalls at modified N-termini; a single mass is compatible with more than one sequence once you allow common modifications.

The practical consequence is that any concentration figure downstream inherits the uncertainty in the formula. This is why what is ps r3 peptide cannot be answered from the name and then set aside: if the molecular mass is not fixed, then a molarity calculated from a weighed mass is only as good as the mass you assumed. In my own notes I record the mass printed on the lot document, the method used to obtain it, and whether an actual spectrum was attached, because those three things together tell me how much weight the number can carry.

Receptor targets and the downstream signalling I could actually trace

Vendor descriptions of ps r3 generally place it near the incretin axis, and I understand why: the compounds it gets shelved next to are glp-1 receptor agonists and the newer multi-agonist peptides. But shelving is not evidence. When I went looking for a peer-reviewed binding affinity table that names ps r3 specifically, I did not find one. What I found instead were affinity and potency tables for the reference compounds, which is a different thing, and conflating the two is the single most common error I see in write-ups of these codes.

The readouts themselves are worth describing because they are measurable and well documented for the reference molecules. cAMP accumulation assays report receptor activation through gs coupling. beta-arrestin recruitment assays report a second, partly independent limb of the signalling and are the usual way people discuss biased agonism. ERK1/2 phosphorylation and receptor internalisation readouts show up as further downstream or trafficking measures. In the papers I read, these are reported with actual curves, emax values and confidence intervals, which is exactly the level of detail that is missing for ps r3.

So my position is a split one. The signalling architecture is real and well characterised for the class; the claim that ps r3 engages it with any particular potency or selectivity is, in the material I can reach, unmeasured. I would rather write that down than dress an inference up as pharmacology. Where I do use class reasoning, I use it to generate a hypothesis I could test in vitro, not to describe an outcome. That distinction is the entire method of this notebook.

Solvents and concentration ranges that recur in the in vitro methods sections

The handling literature is the part of this topic I can treat most concretely, because methods sections actually print their conditions. For lyophilised research peptides the pattern I see repeatedly is a concentrated stock made in a small volume of a solubilising vehicle, followed by dilution into buffered assay medium. Sterile water or dilute acetic acid appears for peptides that carry a net positive charge; a small percentage of dmso appears where solubility in water is poor; and the working dilutions land in the nanomolar to low micromolar range for receptor assays, with higher ranges used for cytotoxicity or uptake work.

Three details in those methods sections changed how I read them. First, the diluent matters as much as the solvent: buffer composition, pH and the presence of a carrier protein change the free concentration at the receptor, and papers that skip it are hard to compare. Second, plastic adsorption is real for hydrophobic sequences, which is why low-binding tubes and a brief carrier protein in the diluent show up so often. Third, the number people quote as a working concentration is usually a nominal one, calculated rather than measured, and aliquot storage history moves it.

I keep a separate page on ps r3 peptide reconstitution where I go through this in more detail, because it deserves more room than a pillar can give it. For this page the summary is enough: treat every concentration as nominal until a measurement says otherwise, record the vehicle alongside the number, and never assume that a range printed for one peptide transfers to another. Everything here is laboratory handling only; none of it describes administration to humans or animals.

Solvents and handling conditions I see repeatedly in peptide methods sections
Stage	What the methods sections commonly state	What I watch for
Stock solution	Small volume of sterile water, dilute acetic acid, or a low percentage of dmso	Whether the vehicle is stated at all, and its final percentage in assay
Working dilution	Buffer at physiological pH, sometimes with a carrier protein	Adsorption to plastic and the resulting loss of free concentration
Assay range	Nanomolar to low micromolar for receptor work	Whether the range was measured or simply calculated from a weighed mass
Storage of aliquots	Single-use frozen aliquots, minimal freeze-thaw	Repeated thawing, which is where most of my own losses came from

How the structure differs from glp-1 and glp-3 class compounds

Comparing ps r3 to the glp-1 class is the most instructive thing I did, mostly because it shows how much structural information a named compound carries and how little a code carries. Native glp-1 is cleaved rapidly by dpp-4, and the medicinal chemistry of the class is largely the story of defeating that: substitution at position 8, fatty acid acylation to recruit albumin, or fusion to a larger carrier. semaglutide is associated with novo nordisk and carries an acylated side chain; tirzepatide is associated with eli lilly and adds gip activity. These are trade names I cite for structural comparison only, with no endorsement or affiliation implied.

The glp-3 label is where I have to be most careful, because it is used loosely. In the material I read it usually refers to multi-agonist peptides that engage glp-1, gip and glucagon receptors, of which retatrutide is the most frequently named example. retatrutide is a trade name associated with eli lilly; again, comparison only, no endorsement implied. The structural point is that these are engineered backbones with deliberately balanced potency ratios, and that balance is something you measure, not something you infer from a name.

Against that, ps r3 has no comparable published anatomy. I cannot place its substitutions, its acylation state if any, or its receptor selectivity, because the sequence is not in the record. The honest comparison is therefore structural in method rather than in detail: for the named compounds I can read a structure and predict behaviour, and then check the prediction against published data; for ps r3 I can only wait for the analytical work on a specific lot. I have a dedicated note on glp-3 rt peptide mechanism and another comparing ps r3 peptide retatrutide, both of which go further than I can here.

Structural features I compare across the glp-1 class, the multi-agonist class, and ps r3
Feature	glp-1 class compounds	glp-3 / multi-agonist compounds	ps r3 as far as I can tell
Backbone	Analogue of the native sequence with position 8 substitution to slow dpp-4 cleavage	Longer hybrid backbones combining glp-1, gip and glucagon elements	Not published; I have no sequence to compare against
Half-life strategy	Fatty acid acylation for albumin binding, or fusion to a larger carrier	Acylation plus further substitution; some are peptide hybrids	Unknown; vendor notes often claim extension with no method
Receptor engagement	Single receptor, thoroughly characterised	Two or three receptors with deliberately balanced potency	Asserted in vendor copy; no peer-reviewed affinity table found
Analytical handle	Published hplc and ms methods exist	Published hplc and ms methods exist	Lot-specific certificate only

HPLC and MS: the impurity profiles that recur in the data I read

Analytical chemistry is where I stop being sceptical and start being grateful, because chromatograms and spectra are the closest thing to ground truth available for a code-named peptide. The standard identity check is reversed-phase hplc with a shallow acetonitrile gradient under trifluoroacetic acid or formic acid, detection at 214 or 220 nm where the amide bond absorbs. Purity is then reported as area percent, which is a chromatographic statement and not a statement about mass fraction; those two numbers diverge whenever an impurity absorbs differently at the chosen wavelength, and they diverge in the direction that flatters the sample.

The recurring impurity classes are remarkably consistent across peptides made by solid-phase synthesis, and learning to read them changed how I look at a certificate. Deletion sequences come from an incomplete coupling step and show as a mass offset of one residue. Truncated species come from chain termination and elute early and broad. Oxidation adds roughly 16 Da per event on met or trp. Deamidation adds about 1 Da on asn or gln and is accelerated at higher pH. Residual trifluoroacetate is invisible at 214 nm and has to be measured separately. Aggregates show late and broad.

On the mass side, what I actually want is the charge-state envelope and its deconvoluted mass, not a single printed number. A spectrum tells me whether the envelope is clean, whether there is a sodium or potassium adduct series I should discount, and whether the base peak really corresponds to the claimed species. Where a certificate gives a mass with no spectrum and no method, I treat it as a claim rather than a measurement, and that single habit has saved me more confusion than any other thing in this notebook.

Impurity classes that recur in the chromatograms and spectra I read
Impurity class	Typical origin	How it shows up in the data
Deletion sequences	Incomplete coupling during solid-phase synthesis	Mass offset equal to one residue, earlier hplc peak
Truncated sequences	Chain termination during assembly	Short, more polar species, broad early peak
Oxidised residues	Met or trp oxidation in storage or in solution	About plus 16 Da per oxidation event in ms
Deamidation	Asn or gln conversion, faster at higher pH	About plus 1 Da, small shoulder on the main peak
Residual counter-ion	Trifluoroacetate left from cleavage and purification	Ion chromatography; not visible at 214 nm
Aggregates	Repeated freeze-thaw or high concentration	Late-eluting broad peak, light scattering signal

Lyophilised presentation and storage stability

Almost every research peptide I have handled arrives as a lyophilised solid, and the physical form tells you something before any instrument does. A well-formed cake or plug at the bottom of the vial suggests controlled freezing and a properly run cycle; a loose powder that has migrated up the glass suggests the material was disturbed or warmed after drying; a collapsed or discoloured cake suggests a cycle that went wrong. None of these observations are quantitative, and I would never report one as a purity result, but they are the cheapest signal available and I record them every time.

The stability literature I read is fairly consistent about the variables that matter: temperature, residual moisture, oxygen exposure and the number of freeze-thaw cycles a solution has been through. Dry peptide under inert gas at low temperature is the condition most often reported as stable for long periods; once in solution, the same material is far less forgiving, and the peptide content of a stored solution drifts downward through adsorption and slow chemical change. Oxidation and deamidation are the two chemical routes that come up most often, and both are slowed rather than stopped by cold.

My own handling practice follows from that, and it is deliberately boring. I bring a vial to room temperature before opening so that moisture does not condense onto cold solid, I split reconstituted material into single-use aliquots rather than thawing one tube repeatedly, I record the date and solvent on every aliquot, and I never carry a solution forward past the point where I would trust its concentration. This is laboratory housekeeping, nothing more; it is not a protocol for human or animal administration and it should not be read as one.

Let the sealed vial reach room temperature before opening, so moisture does not condense onto cold lyophilised solid.
Record the physical appearance of the cake at first opening; it is a cheap, non-quantitative signal about handling history.
Split any reconstituted material into single-use aliquots and label each with solvent, nominal concentration and date.
Keep a written freeze-thaw count, because most of the drift I have measured correlated with cycle number rather than elapsed time.
Re-check identity and purity on any lot that has been stored for a long period rather than assuming the original certificate still describes it.

Which fields of a certificate of analysis I actually read first

A certificate of analysis is the one document that travels with the material, so I read it in a fixed order rather than top to bottom. Identity comes first: is there a mass measurement, what method produced it, and is a spectrum attached. Purity comes second, and I read it narrowly as area percent at a stated wavelength with a stated gradient and column. A purity figure with no method attached is not a measurement, it is an opinion, and I have seen the same lot described at two different percentages on two documents that differed only in wavelength.

Peptide content is the field most people skip and the one I now insist on. Lyophilised material contains water and counter-ion, so the mass you weigh is not the mass of peptide you have. Without a content figure, every molarity you compute from a weighing carries an unstated error, and that error propagates into every downstream number. Counter-ion content and residual solvent belong in the same category: they are not purity issues, they are accounting issues, and accounting is what makes a concentration reproducible between two labs.

Finally I look at the metadata: batch number, date of analysis, method reference and an appearance description. Those let me compare lots over time, which is the only way to notice drift in a supplier process. Where a document is thin, I say so in my notes rather than filling the gap with an assumption. If you want the reasoning behind the document review I use across the whole series, it sits in the research use only statement page alongside the limits I place on these notes.

Fields of a certificate of analysis, in the order I read them
Field	Why I read it	What makes me discount the document
Identity by ms	Confirms the measured mass matches the claimed species	A printed mass with no spectrum and no method
Purity by hplc	Area percent is the only purity number most labs produce	Purity quoted without gradient, column or wavelength
Peptide content	Separates peptide mass from water and counter-ion	Omitted entirely, which shifts every downstream calculation
Counter-ion and residual solvent	Affects weighing, solubility and assay compatibility	No value given at all
Batch, date, method reference	Lets me compare lots and notice process drift	A batch number with no analytical method attached
Appearance description	Cake versus powder tells me about handling history	No description, or a generic one used for every lot

Where the literature is thin, and where it argues with itself

The largest gap is also the simplest to state: I have found no peer-reviewed primary paper that characterises ps r3 as a molecule. Vendor application notes are not peer review, and a catalogue description is not a methods section. That means every pharmacological statement I can make about the compound is borrowed from a neighbouring molecule, and borrowing is exactly the move I am trying to train myself out of. This is also why the question what is ps r3 peptide stays open in my notes rather than being closed with a confident paragraph.

The second gap is a disagreement rather than a silence. Two incompatible readings of the R3 suffix circulate in the material I collected. One reads it as a receptor-selectivity marker, implying that the number encodes which receptor the compound was designed around. The other reads it as a formulation generation, implying that the number encodes a release or stability iteration on a shared scaffold. These readings make different predictions, and the public record I can reach does not adjudicate between them. I hold both loosely and note which one a given document appears to assume.

What would change my mind is specific and short. A deposited sequence with an associated analytical dataset. An independent replication of a binding result by a group that names the compound and shows its chromatogram. A structure, whether by crystallography, cryo-EM or NMR, with coordinates I can actually open and inspect. Until one of those exists, I would rather describe the shape of the gap than paper over it, because the shape of the gap is the most informative thing on this page, and pretending otherwise has misled me before.

My own reading order for anyone retracing this path

If you want to work through this material the way I did, the order matters more than the volume. I made the mistake of starting with the codes themselves and spent several weeks going in circles, because every document about ps r3 quietly assumes the context that no document about ps r3 ever supplies, and I had no way to notice the assumption at the time. Starting with the general literature makes the specific gaps obvious instead of confusing, and it also makes vendor copy much easier to read critically.

So I would begin with peptide structure and bonding, which sounds elementary and is not: residue composition, backbone direction, the amide chromophore, and why a peptide has a charge state at all. My note on the structural unit of peptides and proteins is where I put that foundation. Then receptor pharmacology and the assay formats used to measure activation. Then analytical chemistry, because hplc and ms are what let you evaluate any claim made about any lot. Only then the codes.

The last step is the one people skip: keep your own record. Write down the lot, the document, the numbers and the date, and separate measurement from inference in your own notes as you go. That habit is what turned this from a folder of bookmarks into something I can actually reason with. If you came here asking what is ps r3 peptide, my hope is that the answer you leave with is not a definition but a method.

Peptide structure first: composition, backbone direction, charge state and the amide chromophore.
Receptor pharmacology second: how activation is measured, and what a potency number actually reports.
Analytical chemistry third: reversed-phase hplc, mass spectrometry, and how to read both critically.
Only then the codes themselves, read against the foundation rather than instead of it.
Keep a dated record per lot, with measurement and inference written in separate columns.
Revisit the ps r3 peptide research applications note once the foundation is in place.

Frequently asked questions

What peptide is ps-r3?

In my reading, ps-r3 is a vendor series code rather than a published peptide name. I have not found a registry entry, a deposited sequence or a peer-reviewed paper that defines its composition, so the most I can say is that it is a synthetic research peptide sold under a catalogue label. What is in a given vial has to be established by analysis of that lot, not by looking the name up.

Whats ps-r3 peptide?

It is the same question written as shorthand, and it deserves the same careful answer. ps-r3 peptide is a supplier code for a lyophilised research peptide; the public record does not fix a single accepted sequence, identifier or molecular value for it. If you see a site state one confidently, look for the spectrum or the registry entry behind the number before you accept it.

Is ps-r3 the same thing as ps r3?

As far as I can tell, yes: the hyphen is a writing convention rather than a chemical distinction. I see both forms used for the same catalogue item, alongside ps r3 peptide and psr3. Because the underlying record is thin, I treat spelling variants as one topic and check the batch number instead of the punctuation when I need to know which material a document is describing.

Is there an official CAS number for ps r3 peptide?

Not one I can verify. I searched the public sources available to me and found no registry assignment that I would cite, so I do not print a number here. Where a catalogue shows one, I would want to see it resolve to a defined structure before treating it as anything other than a formatting artefact.

Where does this site list pricing or shipping information?

It does not. I keep no commercial information on these pages, no pricing, no shipping details, no payment or refund terms and no vendor recommendations. The notes exist to record what the literature and the lot documents say about laboratory research material, and mixing commerce into that would undermine the only thing the notebook has going for it.

How is ps r3 different from retatrutide?

retatrutide is a named multi-agonist peptide with published structural and pharmacological work behind it, and it is a trade name associated with eli lilly, cited here for comparison only with no endorsement implied. ps r3 has, as far as I can reach, none of that published anatomy. The comparison is therefore between a documented molecule and a code whose composition has to be measured per lot.

What should I look for on a certificate of analysis?

I read identity first, meaning a mass measurement with a method and ideally a spectrum attached. Then purity as area percent with the gradient, column and wavelength stated. Then peptide content, counter-ion and residual solvent, because without them a weighed mass does not convert into a reliable concentration. Then batch, date and method reference so I can compare lots over time.

Is ps r3 an approved medicine in any jurisdiction?

No. I have found no approval, no licensed indication and no regulatory authorisation for it anywhere in the public record I can access, and I would not describe it as a medicine under any circumstances. It is a research material for laboratory work, and that framing is the only one these notes support.

Sources & further reading

Search links into public bibliographic databases; the notebook quotes no paywalled full text.